MA35347B1 - Procedes therapeuiques - Google Patents
Procedes therapeuiquesInfo
- Publication number
- MA35347B1 MA35347B1 MA36751A MA36751A MA35347B1 MA 35347 B1 MA35347 B1 MA 35347B1 MA 36751 A MA36751 A MA 36751A MA 36751 A MA36751 A MA 36751A MA 35347 B1 MA35347 B1 MA 35347B1
- Authority
- MA
- Morocco
- Prior art keywords
- therapeutic methods
- hepatitis
- iib
- administration
- compound
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 abstract 2
- 231100000283 hepatitis Toxicity 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un procédé pour le traitement de l'hépatite c chez un humain le nécessitant comprenant l'administration d'un composé de formule (ii) ou (iib) décrites ici ou d'un de ses sels pharmaceutiquement acceptables en combinaison avec un ou plusieurs autres agents thérapeutiques contre l'hépatite c.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161524429P | 2011-08-17 | 2011-08-17 | |
US201161526787P | 2011-08-24 | 2011-08-24 | |
PCT/US2012/051349 WO2013025992A1 (fr) | 2011-08-17 | 2012-08-17 | Procédés thérapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35347B1 true MA35347B1 (fr) | 2014-08-01 |
Family
ID=47715500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36751A MA35347B1 (fr) | 2011-08-17 | 2014-02-12 | Procedes therapeuiques |
Country Status (21)
Country | Link |
---|---|
US (2) | US9119868B2 (fr) |
EP (1) | EP2744342B1 (fr) |
JP (2) | JP6121419B2 (fr) |
KR (2) | KR20140093209A (fr) |
CN (2) | CN106109479A (fr) |
AU (1) | AU2012296446B2 (fr) |
BR (1) | BR112014003556A2 (fr) |
CA (1) | CA2843502C (fr) |
CL (2) | CL2014000394A1 (fr) |
CO (1) | CO6880064A2 (fr) |
CR (1) | CR20140075A (fr) |
DO (1) | DOP2014000030A (fr) |
EA (2) | EA024357B1 (fr) |
ES (1) | ES2735542T3 (fr) |
IL (1) | IL230484A (fr) |
MA (1) | MA35347B1 (fr) |
MX (1) | MX2014001833A (fr) |
PE (1) | PE20141391A1 (fr) |
SG (1) | SG10201606646RA (fr) |
WO (1) | WO2013025992A1 (fr) |
ZA (2) | ZA201400435B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140093209A (ko) * | 2011-08-17 | 2014-07-25 | 글락소스미스클라인 엘엘씨 | 치료 방법 |
ME02588B (fr) * | 2011-08-19 | 2017-06-20 | Glaxo Group Ltd | Composés benzofuranes pour le traitement d'infections par le virus de l'hépatite c |
KR20170083108A (ko) * | 2014-11-10 | 2017-07-17 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | C형 간염에 대한 장기 작용 약학적 조성물 |
AU2015344741A1 (en) * | 2014-11-10 | 2017-05-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination long acting compositions and methods for hepatitis C |
CN105732602B (zh) * | 2015-09-23 | 2017-04-19 | 常州寅盛药业有限公司 | 作为ns4b抑制剂的苯并呋喃类似物 |
CN110799193B (zh) * | 2017-03-21 | 2023-12-12 | 斯克利普斯研究院 | 铜和镍催化的脱羧硼化反应 |
TW202130635A (zh) * | 2019-10-25 | 2021-08-16 | 日商大日本住友製藥股份有限公司 | 新穎取代縮環型化合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5920400A (en) * | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Cell-based assay systems for examining hcv ns3 protease activity |
WO2004041201A2 (fr) * | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Composes de benzofurane, compositions et methodes utilisees pour le traitement et la prophylaxie des infections virales induites par l'hepatite c et des maladies associees |
US20070269420A1 (en) | 2003-11-24 | 2007-11-22 | Chunduru Srinivas K | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases |
EP2015757A4 (fr) * | 2006-05-02 | 2011-01-26 | Anacor Pharmaceuticals Inc | Substances thérapeutiques contenant du bore résistant à l'hydrolyse et méthodes d'utilisation |
EP2187883A2 (fr) | 2007-08-10 | 2010-05-26 | Genelabs Technologies, Inc. | Entités chimiques bicycliques azotées pour traiter les infections virales |
GB0719366D0 (en) * | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
KR20100117073A (ko) * | 2008-02-14 | 2010-11-02 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
WO2009137500A1 (fr) * | 2008-05-05 | 2009-11-12 | Wyeth | Composés de benzofurane substitués en 6 pour traiter l’infection par le virus de l’hépatite c |
WO2011050284A1 (fr) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Agents antiviraux de pyrazolylpyridine |
AR080185A1 (es) * | 2010-02-19 | 2012-03-21 | Glaxo Group Ltd | Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv). |
WO2012067663A1 (fr) * | 2010-11-18 | 2012-05-24 | Glaxo Group Limited | Composés |
WO2013025975A1 (fr) * | 2011-08-17 | 2013-02-21 | Glaxosmithkline Llc | Traitements combinés pour l'hépatite c |
KR20140093209A (ko) * | 2011-08-17 | 2014-07-25 | 글락소스미스클라인 엘엘씨 | 치료 방법 |
ME02588B (fr) * | 2011-08-19 | 2017-06-20 | Glaxo Group Ltd | Composés benzofuranes pour le traitement d'infections par le virus de l'hépatite c |
EP2747569A4 (fr) * | 2011-08-24 | 2015-07-08 | Glaxosmithkline Llc | Traitements combinés contre l'hépatite c |
-
2012
- 2012-08-17 KR KR1020147007080A patent/KR20140093209A/ko active Application Filing
- 2012-08-17 CN CN201610457657.XA patent/CN106109479A/zh active Pending
- 2012-08-17 EP EP12824599.0A patent/EP2744342B1/fr active Active
- 2012-08-17 SG SG10201606646RA patent/SG10201606646RA/en unknown
- 2012-08-17 PE PE2014000183A patent/PE20141391A1/es not_active Application Discontinuation
- 2012-08-17 BR BR112014003556A patent/BR112014003556A2/pt not_active IP Right Cessation
- 2012-08-17 KR KR1020187034213A patent/KR101975233B1/ko active IP Right Grant
- 2012-08-17 CN CN201280039778.2A patent/CN103929965B/zh not_active Expired - Fee Related
- 2012-08-17 US US14/239,184 patent/US9119868B2/en not_active Expired - Fee Related
- 2012-08-17 CA CA2843502A patent/CA2843502C/fr not_active Expired - Fee Related
- 2012-08-17 EA EA201490199A patent/EA024357B1/ru not_active IP Right Cessation
- 2012-08-17 EA EA201690327A patent/EA201690327A1/ru unknown
- 2012-08-17 MX MX2014001833A patent/MX2014001833A/es unknown
- 2012-08-17 AU AU2012296446A patent/AU2012296446B2/en not_active Ceased
- 2012-08-17 ES ES12824599T patent/ES2735542T3/es active Active
- 2012-08-17 JP JP2014526244A patent/JP6121419B2/ja active Active
- 2012-08-17 WO PCT/US2012/051349 patent/WO2013025992A1/fr active Application Filing
-
2014
- 2014-01-16 IL IL230484A patent/IL230484A/en active IP Right Grant
- 2014-01-20 ZA ZA2014/00435A patent/ZA201400435B/en unknown
- 2014-02-12 MA MA36751A patent/MA35347B1/fr unknown
- 2014-02-13 CO CO14031175A patent/CO6880064A2/es unknown
- 2014-02-17 CL CL2014000394A patent/CL2014000394A1/es unknown
- 2014-02-17 DO DO2014000030A patent/DOP2014000030A/es unknown
- 2014-02-17 CR CR20140075A patent/CR20140075A/es unknown
-
2015
- 2015-04-17 ZA ZA2015/02595A patent/ZA201502595B/en unknown
- 2015-07-20 US US14/803,478 patent/US10238678B2/en not_active Expired - Fee Related
-
2016
- 2016-02-05 CL CL2016000300A patent/CL2016000300A1/es unknown
-
2017
- 2017-03-29 JP JP2017064038A patent/JP2017165732A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35347B1 (fr) | Procedes therapeuiques | |
CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
TN2014000128A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
UA115320C2 (uk) | Інгібітори кінази | |
MA31358B1 (fr) | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
PH12016502355B1 (en) | Pharmaceutical composition | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
EA201400358A1 (ru) | Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с | |
TN2009000444A1 (en) | Combination therapy with a compound acting as a plateletadp receptor inhibitor | |
BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
MY151295A (en) | Pyrimidyl indoline compound | |
EA201391337A1 (ru) | Ингибиторы hsp90 | |
MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
PH12015500012A1 (en) | Benzodioxole derivative and preparation method and use thereof | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |